DCGI nod for Glenmark Pharma clinical trials on Favipiravir antiviral tablets for COVID-19 patients
150 subjects with mild to moderate COVID-19 will be randomised in the study in a 1:1 ratio to Favipiravir with standard supportive care or standalone standard supportive care.